Does Artelo Biosciences (USA Stocks:ARTL) have persistent basic indicators based on the latest rise?

All Stories . Fundamentals . 
Raphi Shpitalnik .  Story
ARTL Stock  USD 2.09  0.01  0.48%   
Raphi Shpitalnik
By Raphi Shpitalnik
Macroaxis Story
Artelo Biosciences Current Ratio is quite stable at the moment as compared to the past year. The company's current value of Current Ratio is estimated at 4.96. Debt to Equity Ratio is expected to rise to 0.16 this year, although the value of Earnings before Tax will most likely fall to (6.9 M). Artelo Biosciences is scheduled to announce its earnings today. Many investors are getting excited about pharmaceuticals space, let's analyze if Artelo Biosciences fundamentals are strong enough to attract traders. We will cover the possibilities of making Artelo Biosciences into a steady grower in March. Artelo Biosciences follows the market closely. We can now inspect Artelo as a potential investment option for your portfolios.
Published over two weeks ago
View all stories for Artelo Biosciences | View All Stories
Macroaxis uses a strict editorial review process to publish our stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Vlad Skutelnik

We provide trade advice to complement the prevailing expert consensus on Artelo Biosciences. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Artelo Biosciences income statement, its balance sheet, and the statement of cash flows. Potential Artelo Biosciences investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Artelo Biosciences investors may use each financial statement separately, they are all related. The changes in Artelo Biosciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Artelo Biosciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
The goal of Artelo Biosciences fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Artelo Biosciences performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Artelo Biosciences shares is the value that is considered the true value of the share. If the intrinsic value of Artelo is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Artelo Biosciences.
Please read more on our fundamental analysis page.

Are Artelo Biosciences Earnings Expected to grow?

The future earnings power of Artelo Biosciences involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Artelo Biosciences factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Artelo Biosciences stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Artelo expected earnings.

How does Artelo utilize its cash?

To perform a cash flow analysis of Artelo Biosciences, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Artelo Biosciences is receiving and how much cash it distributes out in a given period. The Artelo Biosciences cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Artelo Biosciences Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (5.67 Million)

Detailed Perspective On Artelo Biosciences

The latest rise in Artelo Biosciences short term price appreciation could raise concerns from institutional investors as the firm is trading at a share price of 2.87 on very low momentum in volume. The company executives have successfully maneuvered the firm at convenient times to take advantage of all market conditions in January. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.12. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Artelo Biosciences partners.
 2018 2019 2022 2023 (projected)
Current Assets4.44 M2.34 M2.69 M2.9 M
Total Assets6.48 M4.38 M5.03 M5.43 M

Asset Utilization

One of the ways to look at asset utilization of Artelo is to check how much profit was generated for every dollar of assets it reports. Artelo Biosciences shows a negative utilization of assets of -0.28 percent, losing $0.002775 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Artelo Biosciences shows how discouraging it operates for each dollar spent on its assets.


Current Assets
2.9 M		Assets Non Current
2 M		Goodwill
1.8 M
Current Assets2.9 Million42.99
Assets Non Current2.02 Million29.97
Goodwill1.82 Million27.05

How will Artelo institutional investors react to the next slide?

Standard deviation is down to 3.1. It may entail a possible volatility slide. Artelo Biosciences currently demonstrates below-average downside deviation. It has Information Ratio of 0.11 and Jensen Alpha of 0.34. However, we advise investors to further question Artelo Biosciences expected returns to ensure all indicators are consistent with the current outlook about its relatively low value at risk. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Artelo Biosciences' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Artelo Biosciences' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Takeaway on Artelo Biosciences Investment

Whereas other entities in the biotechnology industry are either recovering or due for a correction, Artelo Biosciences may not be performing as strong as the other in terms of long-term growth potentials. With an optimistic outlook on your 90 days horizon, it may be a good time to take up new shares of Artelo or increase your existing holdings in the Stock as it seems the potential growth has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Artelo Biosciences.

Editorial Staff

Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI. View Profile
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Artelo Biosciences. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2023 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY